ESPE Abstracts

Objectives: Children with growth hormone deficiency (GHD) are usually treated with once-daily injections of recombinant human growth hormone (rhGH). Somatrogon is a long-acting rhGH (LAGH) approved in the EU and other countries for once-weekly treatment of children with short stature. The Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES) study will assess the long-term safety and effectiveness of once-weekly somatrogon and once-daily rhGH prepar...

Background: Thyrotoxicosis in neonates is a life-threatening condition that can be associated with lasting neurologic problems. Most cases are seen in neonates born to mothers with Graves’ disease in which thyroid stimulating immunoglobulin (TSI) is transferred to the foetus and results in hyperthyroidism. Hypothyroidism due to topical iodine use has been reported in neonates, but thyrotoxicosis has never been described in this age, while in adults is a known entity. We h...

Background: Carbimazole is widely used in the treatment of Graves’ disease and is well tolerated but can produce adverse effects in 5% of cases. Urticaria, which can develop as a drug reaction to carbimazole responds to withdrawal of the drug and symptomatic management. Urticaria is also a rare manifestation of thyrotoxicosis and does not respond to treatment, but regresses rapidly with the control of underlying hyperthyroidism.Objective and hypothe...